131 related articles for article (PubMed ID: 8511115)
21. Clinical use of tumor markers in oncology.
Jacobs EL; Haskell CM
Curr Probl Cancer; 1991; 15(6):299-360. PubMed ID: 1760927
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
Cohen BL; Gomez P; Omori Y; Duncan RC; Civantos F; Soloway MS; Lokeshwar VB; Lokeshwar BL
Int J Cancer; 2006 Sep; 119(5):1082-7. PubMed ID: 16557596
[TBL] [Abstract][Full Text] [Related]
23. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
[TBL] [Abstract][Full Text] [Related]
25. Clinical uses of tumor markers: a critical review.
Duffy MJ
Crit Rev Clin Lab Sci; 2001 Jun; 38(3):225-62. PubMed ID: 11451209
[TBL] [Abstract][Full Text] [Related]
26. Dynamic use of tumor markers, rationale-clinical applications and pitfalls.
Gion M; Mione R; Barioli P; Dittadi R
Anticancer Res; 1996; 16(4B):2279-84. PubMed ID: 8694556
[TBL] [Abstract][Full Text] [Related]
27. The search for biomarkers of metastatic seminoma.
Ruf CG; Khalili-Harbi N; Sachs S; Isbarn H; Wagner W; Matthies C; Meineke V; Fisch M; Chun FK; Abend M
J Urol; 2013 Sep; 190(3):1046-51. PubMed ID: 23583226
[TBL] [Abstract][Full Text] [Related]
28. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
Cole LA; Nam JH
Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of novel tumour markers.
Rhodes JM
Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801
[TBL] [Abstract][Full Text] [Related]
30. [Metastasis and markers].
Trinchieri A; Rovera F; Longo G; Del Nero A; Zanetti G; Austoni E
Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):27-30. PubMed ID: 1373913
[TBL] [Abstract][Full Text] [Related]
31. [What importance do tumor markers have in life insurance medicine?].
Binsack T; Kraus HK
Versicherungsmedizin; 1990 Dec; 42(6):157-62. PubMed ID: 2291265
[TBL] [Abstract][Full Text] [Related]
32. Biomarker discovery in ovarian cancer.
Tung CS; Wong KK; Mok SC
Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
[TBL] [Abstract][Full Text] [Related]
33. [The accuracy of CT and tumor markers in the detection of a recurrent ovarian carcinoma].
Wakabayashi Y; Ishida J; Kotake F; Hirose M; Kawana K; Abe K; Amino S; Negishi Y; Akiya K
Gan No Rinsho; 1989 Sep; 35(10):1127-31. PubMed ID: 2550684
[TBL] [Abstract][Full Text] [Related]
34. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
35. [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Postepy Hig Med Dosw (Online); 2007; 61():122-8. PubMed ID: 17369780
[TBL] [Abstract][Full Text] [Related]
36. Immunocytochemical evaluation of primary human esophageal carcinomas and their xenografts for keratin, beta-chorionic gonadotropin, placental lactogen, alpha-fetoprotein, carcinoembryonic antigen, and nonspecific cross-reacting antigen.
Burg-Kurland CL; Purnell DM; Combs JW; Valerio MG; Harris CC; Trump BF
Cancer Res; 1986 Nov; 46(11):5730-7. PubMed ID: 2428482
[TBL] [Abstract][Full Text] [Related]
37. Tumor markers: myths and facts unfolded.
Faria SC; Sagebiel T; Patnana M; Cox V; Viswanathan C; Lall C; Qayyum A; Bhosale PR
Abdom Radiol (NY); 2019 Apr; 44(4):1575-1600. PubMed ID: 30498924
[TBL] [Abstract][Full Text] [Related]
38. [Critical study of current tumoral markers].
Touitou Y; Bogdan A
Bull Cancer; 1988; 75(3):247-62. PubMed ID: 2453233
[TBL] [Abstract][Full Text] [Related]
39. [Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes].
Nonomura N; Imazu T; Harada Y; Nozawa M; Ono Y; Fukui T; Nishimura K; Okuyama A
Hinyokika Kiyo; 1999 Aug; 45(8):593-7. PubMed ID: 10500969
[TBL] [Abstract][Full Text] [Related]
40. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
